1. A compound of formula
in which
R1 represents phenyl,
whereby phenyl is substituted with 1 to 3 substituents, whereby the substituents are selected independently of one another from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, (C1-C4)-alkyl and (C1-C4)-alkoxy,
wherein
(C1-C4)-alkyl and (C1-C4)-alkoxy in turn may be substituted one to three times identically or differently with radicals selected from the group consisting of halogen, cyano, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl and 4- to 7-membered heterocyclyl,
whereby the last-mentioned cycloalkyl and heterocyclyl radicals in turn may each be substituted up to three times identically or differently with halogen, cyano, (C1-C4)-alkyl, trifluoromethyl, hydroxy, (C1-C4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino, and
R2 represents phenyl,
whereby phenyl is substituted with 1 to 3 substituents, whereby the substituents are selected independently of one another from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, (C1-C4)-alkyl and (C1-C4)-alkoxy,
wherein
(C1-C4)-alkyl and (C1-C4)-alkoxy in turn may be substituted one to three times identically or differently with radicals selected from the group consisting of halogen, cyano, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl and 4- to 7-membered heterocyclyl,
whereby the last-mentioned cycloalkyl and heterocyclyl radicals in turn may each be substituted up to three times identically or differently with halogen, cyano, (C1-C4)-alkyl, trifluoromethyl, hydroxy, (C1-C4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino,
or one of the salts thereof.
2. The compound of claim 1, whereby
R1 represents phenyl,
whereby phenyl is substituted with 1 to 2 substituents, whereby the substituents are selected independently of one another from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, (C1-C4)-alkyl and (C1-C4)-alkoxy, and
R2 represents phenyl,
whereby phenyl is substituted with 1 to 2 substituents, whereby the substituents are selected independently of one another from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, (C1-C4)-alkyl and (C1-C4)-alkoxy,
wherein
(C1-C4)-alkoxy in turn may be substituted one or three times identically or differently with radicals selected from the group consisting of halogen, cyano, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl and 4- to 7-membered heterocyclyl,
whereby the last-mentioned cycloalkyl and heterocyclyl radicals in turn may each be substituted up to three times identically or differently with halogen, cyano, (C1-C4)-alkyl, trifluoromethyl, hydroxy, (C1-C4)-alkoxy, trifluoromethoxy, oxo, amino, mono-(C1-C4)-alkylamino and di-(C1-C4)-alkylamino,
or one of the salts thereof.
3. The compound of claim 1, whereby
R1 represents phenyl,
whereby phenyl is substituted with 1 to 2 substituents, whereby the substituents are selected independently of one another from the group consisting of halogen, cyano, trifluoromethyl, methyl and methoxy,
R2 represents phenyl,
whereby phenyl is substituted with 1 to 2 substituents, whereby the substituents are selected independently of one another from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy, methyl and (C1-C3)-alkoxy,
or one of the salts thereof.
4. The compound of claim 1, corresponding to formula
in which
R3 represents halogen or cyano,
R4 represents hydrogen or halogen,
R5 represents halogen, cyano or trifluoromethyl, and
R6 represents hydrogen or halogen,
or one of the salts thereof.
5. The compound of claim 4, whereby
R3 represents fluorine, chlorine or cyano,
R4 represents hydrogen, chlorine or fluorine,
R5 represents fluorine, chlorine or cyano, and
R6 represents hydrogen, chlorine or fluorine,
or one of the salts thereof.
6. The compound of claim 4, whereby
R3 represents chlorine or cyano,
R4 represents hydrogen or fluorine,
R5 represents chlorine or cyano, and
R6 represents hydrogen or fluorine,
or one of the salts thereof.
7. A method for preparing a compound of formula (I) of claim 1, comprising reacting a compound of formula
in which
R1 and R2 have the meaning given in claim 1,
with imidazolidin-4-one or with a salt of imidazolidin-4-one.
8. A method for preparing a compound of formula (I) of claim 1, comprising reacting a compound of formula
in which
R2 has the meaning given in claim 1,
under Suzuki coupling conditions with a compound of formula
R1-Q\u2003\u2003(V),
in which
R1 has the meaning given in claim 1 and
Q represents \u2014B(OH)2, a boronic acid ester, preferably boronic acid pinacol ester, or \u2014BF3\u2212K+.
9. A method for preparing a compound of formula (I) of claim 1, comprising reacting a compound of formula
in which
R1 has the meaning given in claim 1,
under Suzuki coupling conditions with a compound of formula
R2-Q\u2003\u2003(VII),
in which
R2 has the meaning given in claim 1 and
Q represents \u2014B(OH)2, a boronic acid ester, preferably boronic acid pinacol ester, or \u2014BF3\u2212K+.
10. A method for the manufacture of a medicament for the treatment of diseases comprising mixing a compound of claim 1 with an inert, non-toxic, pharmaceutically acceptable excipient.
11. A method for the manufacture of a medicament for the treatment of retroviral diseases comprising mixing a compound of claim 1 with an inert, non-toxic, pharmaceutically acceptable excipient.
12. The method of claim 11, whereby said retroviral disease is an infection with the HI virus.
13. A medicament comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one further active compound.
14. A medicament comprising a therapeutically effective amount at least one compound of claim 1 in combination with at least one inert, non-toxic, pharmaceutically acceptable excipient.
15. A method for controlling viral diseases in humans and animals by administering an antivirally effective amount of at least one compound of claim 1 or a medicament of claim 13 or 14 to a human or animal in need thereof.
16. The method of claim 15, whereby said viral disease is a retroviral disease.
17. The method of claim 16, whereby said retroviral disease is an infection with the HI virus.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of operating a networked wager-based gaming machine comprising:
performing one or more security functions in an electronic gaming module, the electronic gaming module connected to a data network by a first data connection;
monitoring power provided to the electronic gaming module; and
in response to detecting a loss of power to the electronic gaming module, performing the one or more security functions in a security interface module, the security interface module connected to the data network by a second data connection, the security interface module receiving power separately from the electronic gaming module.
2. The method of claim 1 wherein the one or more security functions include monitoring door switches.
3. The method of claim 1 wherein the one or more security functions include controlling employee access to the wager-based gaming machine when the power switch is off.
4. The method of claim 1 wherein the electronic gaming module performs the one or more security functions when power is switched on to the electronic gaming module.
5. The method of claim 1 wherein, when the power is switched on to the electronic gaming machine, the electronic gaming module and the security interface module perform the one or more security functions together.
6. The method of claim 1 further comprising monitoring data provided by the electronic gaming module over the first connection, and data provided by the security interface module over the second connection, to identify discrepancies, and issue an alert in response to identification of a discrepancy.
7. A networked electronic wager-based gaming machine comprising:
means for performing one or more security functions in an electronic gaming module, the electronic gaming module connected to a data network by a first data connection;
means for monitoring power provided to the electronic gaming module; and
means for performing the one or more security functions in a security interface module, the security interface module connected to the data network by a second data connection, the security interface module receiving power separately from the electronic gaming machine.